Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience

Background : Dendritic cells (DC) are the most potent antigen‐presenting cells and induce host antitumor immunity through the T‐cell response. A clinical study of immunotherapy using cultured DC loaded with tumor antigen, for patients with metastatic renal cell carcinoma (RCC) was performed.

[1]  W. Linehan,et al.  Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. , 1999, The Journal of urology.

[2]  G. Bartsch,et al.  CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer , 1998, The Lancet.

[3]  H. Ragde,et al.  Report of immune monitoring of prostate cancer patients undergoing T‐cell therapy using dendritic cells pulsed with HLA‐A2‐specific peptides from prostate‐specific membrane antigen (PSMA) , 1998, The Prostate.

[4]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[5]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[6]  D. Hart,et al.  Dendritic cells: unique leukocyte populations which control the primary immune response. , 1997, Blood.

[7]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[8]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[9]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[10]  Liangji Zhou,et al.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Hinke,et al.  Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. , 1996, The Journal of urology.

[12]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[13]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[14]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[15]  N. Vogelzang,et al.  Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[17]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[18]  P. van der Bruggen,et al.  T cell defined tumor antigens. , 1997, Current opinion in immunology.

[19]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[20]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[21]  O RAJKA,et al.  [TUMOR IMMUNOLOGY]. , 1963, Orvosi hetilap.